Stock of the Day

Agios Pharmaceuticals (AGIO)

$35.22

+$1.47 (+4.3%)

Market Cap: $1.93B

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Recent News

• Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 (globenewswire.com)
• Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript (insidermonkey.com)